Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE

Next Previous
X
Search
Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck KGaA

    • Most Recent Events

    • 23 Nov 2022 Results of the integrated safety (n=1083) profile of evobrutinib using pooled data from (NCT02975349, NCT03233230, NCT02975336) multiple sclerosis (MS), rheumatoid arthritis and systemic lupus erythematosus trials, published in the Journal of Neurology, Neurosurgery and Psychiatry.
    • 14 Nov 2022 Results of post hoc pooled analysis assessing the responsiveness of the PROMIS Fatigue 13a and 10a scores and to establish minimal important difference (MID) estimates in SLE populations, presented at the ACR Convergence 2022.
    • 28 Jun 2022 Results of a post hoc analysis presented at the 8th Congress of the European Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top